PFE

Prezzo Pfizer

Closed
PFE
$27,10
-$0,73(-2,62%)

*Data last updated: 2026-04-08 04:08 (UTC+8)

As of 2026-04-08 04:08, Pfizer (PFE) is priced at $27,10, with a total market cap of $154,09B, a P/E ratio of 18,21, and a dividend yield of 6,34%. Today, the stock price fluctuated between $26,78 and $27,60. The current price is 1,19% above the day's low and 1,81% below the day's high, with a trading volume of 40,52M. Over the past 52 weeks, PFE has traded between $21,97 to $28,74, and the current price is -5,70% away from the 52-week high.

PFE Key Stats

Yesterday's Close$27,83
Market Cap$154,09B
Volume40,52M
P/E Ratio18,21
Dividend Yield (TTM)6,34%
Dividend Amount$0,43
Diluted EPS (TTM)1,36
Net Income (FY)$7,77B
Revenue (FY)$62,57B
Earnings Date2026-05-05
EPS Estimate0,77
Revenue Estimate$13,89B
Shares Outstanding5,53B
Beta (1Y)0.388
Ex-Dividend Date2026-01-23
Dividend Payment Date2026-03-06

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOAlbert Bourla
HeadquartersNew York City,NY,US
Official Websitehttps://www.pfizer.com
Employees (FY)75,00K
Average Revenue (1Y)$834,38K
Net Income per Employee$103,60K

Pfizer (PFE) FAQ

What's the stock price of Pfizer (PFE) today?

x
Pfizer (PFE) is currently trading at $27,10, with a 24h change of -2,62%. The 52-week trading range is $21,97–$28,74.

What are the 52-week high and low prices for Pfizer (PFE)?

x

What is the price-to-earnings (P/E) ratio of Pfizer (PFE)? What does it indicate?

x

What is the market cap of Pfizer (PFE)?

x

What is the most recent quarterly earnings per share (EPS) for Pfizer (PFE)?

x

Should you buy or sell Pfizer (PFE) now?

x

What factors can affect the stock price of Pfizer (PFE)?

x

How to buy Pfizer (PFE) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Pfizer (PFE)

K-LinePoet

K-LinePoet

5 ore fa
2026年3月5日, 辉瑞(PFE)披露1笔公司内部人交易情况。高管DAMICO JENNIFER B.于2026年3月4日卖出826股。 **【近期内部交易】** | 披露日期 | 职位 | 姓名 | 交易日期 | 买/卖 | 数量 | 每股成交价/美元 | 总金额/美元 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2026年3月5日 | 高管 | DAMICO JENNIFER B. | 2026年3月4日 | 卖出 | 826 | 26.62 | 2.20万 | | 2026年3月3日 | 高管 | DAMICO JENNIFER B. | 2026年2月27日 | 卖出 | 655 | 27.65 | 1.81万 | | 2026年2月27日 | 董事 | BOURLA ALBERT | 2026年2月25日 | 买入 | 49.16万 | 33.82 | 1662.68万 | | 2026年2月27日 | 高管 | Fonseca Lidia、LANKLER DOUGLAS M、McDermott Michael、SAHNI PAYAL | 2026年2月25日 | 买入 | 27.46万 | 33.82 | 928.72万 | | 2026年2月27日 | 董事 | BOURLA ALBERT | 2026年2月25日 | 卖出 | 46.72万 | 26.92 | 1257.81万 | | 2026年2月27日 | 董事 | BOURLA ALBERT | 2026年2月25日 | 卖出 | 8303 | 27.09 | 22.49万 | | 2026年2月27日 | 高管 | Fonseca Lidia、LANKLER DOUGLAS M、McDermott Michael、SAHNI PAYAL | 2026年2月25日 | 卖出 | 5018 | 27.09 | 13.59万 | | 2026年2月27日 | 高管 | Fonseca Lidia、LANKLER DOUGLAS M、McDermott Michael、SAHNI PAYAL | 2026年2月25日 | 卖出 | 26.10万 | 26.92 | 702.58万 | | 2026年2月27日 | 高管 | McDermott Michael | 2026年2月26日 | 卖出 | 3503 | 27.10 | 9.49万 | | 2026年2月27日 | 高管 | BOSHOFF CHRISTOFFEL | 2026年2月25日 | 卖出 | 6833 | 27.09 | 18.51万 | **【公司资料】** 辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源,通过发现、开发、制造和分销保健产品(包括创新药物和疫苗),为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作,致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作,支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。
0
0
0
0